English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies.

Kloiber, S., Domschke, K., Ising, M., Arolt, V., Baune, B. T., Holsboer, F., et al. (2015). Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies. The Journal of clinical psychiatry, 76(6), e802-e808. doi:10.4088/JCP.14m09212.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-5D9A-9 Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-5D9B-7
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Kloiber, Stefan1, Author              
Domschke, Katharina2, Author
Ising, Marcus1, Author              
Arolt, Volker2, Author
Baune, Bernhard T2, Author
Holsboer, Florian1, Author              
Lucae, Susanne1, Author              
Affiliations:
1Max Planck Institute of Psychiatry, Max Planck Society, ou_1607137              
2external, ou_persistent22              

Content

show
hide
Free keywords: -
 Abstract: OBJECTIVE: Weight gain during psychopharmacologic treatment has considerable impact on the clinical management of depression, treatment continuation, and risk for metabolic disorders. As no profound clinical risk factors have been identified so far, the aim of our analyses was to determine clinical risk factors associated with short-term weight development in 2 large observational psychopharmacologic treatment studies for major depression. METHOD: Clinical variables at baseline (age, gender, depression psychopathology, anthropometry, disease history, and disease entity) were analyzed for association with percent change in body mass index (BMI; normal range, 18.5 to 25 kg/m(2)) during 5 weeks of naturalistic psychopharmacologic treatment in patients who had a depressive episode as single depressive episode, in the course of recurrent unipolar depression or bipolar disorder according to DSM-IV criteria. 703 patients participated in the Munich Antidepressant Response Signature (MARS) project, an ongoing study since 2002, and 214 patients participated in a study conducted at the University of Muenster from 2004 to 2006 in Germany. RESULTS: Lower BMI, weight-increasing side effects of medication, severity of depression, and psychotic symptoms could be identified as clinical risk factors associated with elevated weight gain during the initial treatment phase of 5 weeks in both studies. Based on these results, a composite risk score for weight gain consisting of BMI ≤ 25 kg/m(2), Hamilton Depression Rating Scale (17-item) score > 20, presence of psychotic symptoms, and administration of psychopharmacologic medication with potential weight-gaining side effects was highly discriminative for mean weight gain (F4,909 = 26.77, P = 5.14E-21) during short-term psychopharmacologic treatment. CONCLUSIONS: On the basis of our results, depressed patients with low to normal BMI, severe depression, or psychotic symptoms should be considered at higher risk for weight gain during acute antidepressant treatment. We introduce a new risk score that might be considered in psychopharmacologic decisions for the prevention of weight gain and resulting metabolic disorders.

Details

show
hide
Language(s): eng - English
 Dates: 2015
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 26132689
DOI: 10.4088/JCP.14m09212
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: The Journal of clinical psychiatry
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Memphis, TN 38120, USA : Physicians Postgraduate Press, Inc.
Pages: - Volume / Issue: 76 (6) Sequence Number: - Start / End Page: e802 - e808 Identifier: -